Radioactive drug targets Hard-to-Treat thyroid cancer
NCT ID NCT06991738
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times
Summary
This study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive four infusions over several months and be monitored for safety and effectiveness. The goal is to find a safe dose that can slow or stop the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-DOTA-EB-TATE (a radioactive drug that targets cancer cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with a rare thyroid cancer that has few alternatives.
- What could go wrong
- This is a very early, small trial (18 people) focused on finding a safe dose. It may not work or could have side effects from radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RADIOACTIVE IODINE NON-RESPONSIVE ONCOCYTIC (HURTHLE CELL) THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic test may spare patients from unnecessary thyroid surgery
- Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
- Can an immune booster make radioiodine more effective against thyroid cancer?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can math make thyroid hormone therapy more precise?
- Can AI help surgeons see thyroid cancer more clearly?